Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?
We thank the authors of this letter  written in response to our publication  for their interest and for engaging in the discussion about this important topic. Dr. Cottereau et al.  reiterate the key message from our publication that metabolic tumour volume (MTV) is a strong predictor of prognosis irrespective of the method; however, cut-offs used to divide patients into high and low risk groups by MTV are highly dependent on the patient population and the method used.
The authors indicate that their objective was to discuss the strengths and weaknesses of each segmentation method, which was the purpose of our study. However, they do not conclude that there is an optimal method yet, and indeed the letter’s title seems to suggest that there is not one. We concur that all methods have strengths and limitations and estimate prognosis well, but it is important to reiterate that the widespread adoption of MTV into routine practice will rely on two main factors; the ease...
Compliance with ethical standards
Patient data were extracted from case records and reviewed only by members of the responsible clinical team, in compliance with the UK Data Protection Act; consequently, specific Research Ethics Approval and individual patient consent were not required. Professor Barrington acknowledges support from the National Institute of Health Research (NIHR) [RP-2-16-07-001]. King’s College London and UCL Comprehensive Cancer Imaging Centre is funded by the CRUK and EPSRC, in association with the MRC and Department of Health (England).The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. She has received research funding from Hermes Medical Solutions.
- 3.Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella A, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Fingerle-Rowson G, Knapp A, Mattiello F, Nielsen T, Sellam G, Sahin D, Vitolo U, Trněný M. Baseline PET-derived metabolic tumor volume metrics predict progression-free and overall survival in DLBCL after first-line treatment: results from the phase 3 GOYA study. Blood. 2017.Google Scholar